Your browser doesn't support javascript.
loading
A Mouse Systems Genetics Approach Reveals Common and Uncommon Genetic Modifiers of Hepatic Lysosomal Enzyme Activities and Glycosphingolipids.
Durán, Anyelo; Priestman, David A; Las Heras, Macarena; Rebolledo-Jaramillo, Boris; Olguín, Valeria; Calderón, Juan F; Zanlungo, Silvana; Gutiérrez, Jaime; Platt, Frances M; Klein, Andrés D.
Afiliación
  • Durán A; Centro de Genética y Genómica, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7610658, Chile.
  • Priestman DA; Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.
  • Las Heras M; Centro de Genética y Genómica, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7610658, Chile.
  • Rebolledo-Jaramillo B; Centro de Genética y Genómica, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7610658, Chile.
  • Olguín V; Centro de Genética y Genómica, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7610658, Chile.
  • Calderón JF; Centro de Genética y Genómica, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7610658, Chile.
  • Zanlungo S; Research Center for the Development of Novel Therapeutic Alternatives for Alcohol Use Disorders, Santiago 7610658, Chile.
  • Gutiérrez J; Department of Gastroenterology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330033, Chile.
  • Platt FM; Cellular Signaling and Differentiation Laboratory, School of Medical Technology, Health Sciences Faculty, Universidad San Sebastian, Santiago 7510602, Chile.
  • Klein AD; Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.
Int J Mol Sci ; 24(5)2023 Mar 03.
Article en En | MEDLINE | ID: mdl-36902345
ABSTRACT
Identification of genetic modulators of lysosomal enzyme activities and glycosphingolipids (GSLs) may facilitate the development of therapeutics for diseases in which they participate, including Lysosomal Storage Disorders (LSDs). To this end, we used a systems genetics

approach:

we measured 11 hepatic lysosomal enzymes and many of their natural substrates (GSLs), followed by modifier gene mapping by GWAS and transcriptomics associations in a panel of inbred strains. Unexpectedly, most GSLs showed no association between their levels and the enzyme activity that catabolizes them. Genomic mapping identified 30 shared predicted modifier genes between the enzymes and GSLs, which are clustered in three pathways and are associated with other diseases. Surprisingly, they are regulated by ten common transcription factors, and their majority by miRNA-340p. In conclusion, we have identified novel regulators of GSL metabolism, which may serve as therapeutic targets for LSDs and may suggest the involvement of GSL metabolism in other pathologies.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glicoesfingolípidos / Enfermedades por Almacenamiento Lisosomal Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Int J Mol Sci Año: 2023 Tipo del documento: Article País de afiliación: Chile

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glicoesfingolípidos / Enfermedades por Almacenamiento Lisosomal Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Int J Mol Sci Año: 2023 Tipo del documento: Article País de afiliación: Chile